Curriculum

Targeted Treatment for Major Depressive Disorder: Focus on Residual Symptoms

In this curriculum, you will gain insight into the presentation and management of patients with major depressive disorder (MDD) who experience an inadequate response to therapy, with a focus on residual anhedonia and insomnia.  These learning activities explore the clinical burden of these residual symptoms, the pathophysiology behind them, current treatment deficiencies, and emerging therapies.

Loading... Begin
woman with depression on the couch

CME Information

1.50 AMA PRA Category 1 Credits™, 1.50 ABIM MOC or 1.26 AANP, 1.26 AANP Pharm

Release Date: 12/6/2024

Available for credit until 12/6/2025

Topics

Faculty

Learning Objectives

  • Examine the correlation between unresolved, residual symptoms of major depressive disorder (MDD) and underlying pathophysiology not addressed with current standard-of-care treatments
  • Investigate the disease burden of anhedonia in patients with MDD, including why residual anhedonia requires prompt management
  • Investigate the disease burden of insomnia symptoms in patients with MDD, including why residual insomnia symptoms require prompt management 

Courses

1.50 CME/CE CREDITS

3 Courses

Faculty

Michael Ziffra, MD

Associate Professor, Department of Psychiatry, Northwestern University Feinberg School of Medicine, Chicago, IL

Read More
Jeffrey Rado, MD, MPH, FAPA

Associate Professor, Physician Leader, Collaborative Behavioral Health Program, Director, Clinical Trials Research Program, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL

Read More

Supported By

Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC 

Education Partner

Pri-Med Institute